Live Breaking News & Updates on Khalifa Institute

Stay updated with breaking news from Khalifa institute. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dr Yap on the Continued Investigation of Saruparib in Advanced Solid Tumors

Dr Yap on the Continued Investigation of Saruparib in Advanced Solid Tumors
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

United States , Timothy Yap , Department Of Thoracic Head , Therapeutics Discovery Division , Khalifa Institute For Personalized Cancer Therapy , University Of Texas Md Anderson Cancer Center , Investigational Cancer Therapeutics , Phasei Program , Neck Medical Oncology , Khalifa Institute , Personalized Cancer Therapy , Cancer Center ,

Dr Yap on the Investigation of Saruparib in Solid Tumors

Timothy Yap, MBBS, PhD, FRCP, discusses the rationale for investigating saruparib in advanced solid tumors, such as prostate cancer with genetic mutations. ....

United States , Timothy Yap , Department Of Thoracic Head , Khalifa Institute For Personalized Cancer Therapy , University Of Texas Md Anderson Cancer Center , Therapeutics Discovery Division , Investigational Cancer Therapeutics , Phasei Program , Neck Medical Oncology , Khalifa Institute , Personalized Cancer Therapy , Cancer Center ,

First-in-Class PARP1 Selective Inhibitor Saruparib Shines in Phase 1 Trial of Advanced Solid Tumors

Timothy Yap, MBBS, PhD, FRCP, discusses encouraging data seen with the first-in-class PARP1 selective inhibitor saruparib in solid tumors and how the agent is being further investigated. ....

United States , Timothy Yap , Therapeutics Discovery Division , Translational Research , University Of Texas Md Anderson Cancer Center , Khalifa Institute For Personalized Cancer Therapy , Clinical Development , Investigational Cancer Therapeutics , Phasei Program , Neck Medical Oncology , Cancer Center , Khalifa Institute , Personalized Cancer , Project Optimus ,

Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer

Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , Radiopharm Theranostics , Institut Gustave Roussy , Timothya Yap , Eli Lilly , Clinical Development , Cancer Research United Kingdom , University Of Texas Md Anderson Cancer Center , Translational Research , Baptist Health Systems , Breast Cancer Congress , Bristol Myers Squibb , Khalifa Institute For Personalized Cancer Therapy , Institute For Applied Cancer Science , Therapeutics Discovery Division , Department Of Thoracic Head , Globe Life Sciences , Investigational Cancer Therapeutics , Phasei Program , Neck Medical Oncology , Khalifa Institute , Personalized Cancer Therapy , Cancer Center , Zai Labs , Ono Pharma ,

Dr Yap on Saruparib in BRCA1/2+, PALB2+, or RAD51C/D+ Advanced Solid Tumors

Dr Yap on Saruparib in BRCA1/2+, PALB2+, or RAD51C/D+ Advanced Solid Tumors
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

United States , Timothy Yap , Therapeutics Discovery Division , Department Of Thoracic Head , University Of Texas Md Anderson Cancer Center , Khalifa Institute For Personalized Cancer Therapy , Investigational Cancer Therapeutics , Phasei Program , Neck Medical Oncology , Khalifa Institute , Personalized Cancer Therapy , Cancer Center ,